A Phase 1 Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PolyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML

Inclusion Criteria:

- Subjects with a confirmed diagnosis of:

- International Prognostic Scoring System (IPSS) intermediate-I, intermediate-2 or
high-risk MDS including chronic myelomonocytic leukemia (CMML) or

- Low blast count AML with =< 30% blasts previously classified as refractory
anemia with excess blasts in transformation who have not been previously treated
with a hypomethylating agent

- Patients with IPSS intermediate-1 disease with an isolated deletion of
chromosome 5q must have previously failed treatment with lenalidomide

- Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

- Total bilirubin =< 2 X upper limit of normal (ULN)

- Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and
alanine transaminase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN

- Serum creatinine =< 1.5 X ULN

- Any human leukocyte antigen (HLA) type

- Subjects of child-bearing potential must agree to use adequate contraceptive methods
(e.g., hormonal or barrier method of birth control; abstinence) prior to study entry
and for the duration of study participation; should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study, she
should inform her treating physician immediately

- Subject or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee/Institutional Review Board approved
written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

- Subjects with life-threatening illnesses other than MDS, uncontrolled medical
conditions or organ system dysfunction which, in the investigator's opinion, could
compromise the subject's safety, or put the study outcomes at risk

- AML associated with inv(16); t(I 6;16); t(8;21) or t(1 5;17)

- Subjects with uncontrolled or symptomatic arrhythmias, or any class 3 or 4 cardiac
disease as defined by the New York Heart Association functional classification

- Subjects with symptomatic central nervous system (CNS) disease which is not
adequately controlled

- Subjects who have received prior radiation therapy for extramedullary disease within
2 weeks of first dose

- Subjects with human immunodeficiency virus (HIV) or active infection with hepatitis C
virus (HCV) or hepatitis B virus (HBV)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Subjects who are being treated with systemic corticosteroids

- Subjects who have hypersensitivity to decitabine

- History of auto-immune disease (eg. thyroiditis, lupus) except vitiligo

- Pregnant or nursing female subjects

- Unwilling or unable to follow protocol requirements

- Any condition which in the Investigator's opinion deems the subject an unsuitable
candidate to receive study drug

- Received an investigational agent within 30 days prior to enrollment

- Subjects with other prior malignancies must be disease free for at least 3 years

- Subjects previously treated with an allogeneic stem cell transplant